AgomAb Therapeutics (NASDAQ:AGMB) Coverage Initiated at B. Riley Financial

B. Riley Financial initiated coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research note issued on Thursday, MarketBeat reports. The firm set a “buy” rating and a $34.00 price target on the stock. B. Riley Financial’s price target points to a potential upside of 171.78% from the company’s current price.

Separately, HC Wainwright initiated coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, AgomAb Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

AgomAb Therapeutics Stock Down 3.5%

Shares of AgomAb Therapeutics stock opened at $12.51 on Thursday. AgomAb Therapeutics has a 52-week low of $8.75 and a 52-week high of $17.82. The business has a 50 day moving average price of $11.79.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.